Biological Rationale and ADC Design Principles
Trophoblast cell-surface antigen 2 (TROP2), encoded by the TACSTD2 gene, is a transmembrane calcium signal transducer originally identified in placental trophoblasts that is selectively overexpressed across multiple epithelial malignancies relative to normal tissues. In a pan-cancer analysis of 36,717 tumors, TROP2-high expression was present in 35% of triple-negative breast cancers (TNBC) and 21% of hormone receptor–positive/HER2-negative (HR+/HER2−) tumors, and was associated with significantly shorter overall survival (OS) in breast (hazard ratio [HR] 1.13; P<0.007), colorectal (HR 1.33; P<0.001), and pancreatic cancers (HR 1.31; P<0.001), though not in urothelial or hepatocellular carcinoma 1. TROP2-high tumors harbor distinct mutational landscapes—enriched for TP53 and KRAS mutations—and display a more immune-inflamed microenvironment with greater neutrophil and M1 macrophage infiltration, though TROP2-high breast cancer patients paradoxically experienced worse post-immunotherapy OS (HR 1.91; P=0.022), underscoring tumor-type–specific interactions with immune checkpoint inhibitors (ICI) 1.
TROP2-directed antibody-drug conjugates (ADCs) integrate three components: a humanized anti-TROP2 IgG1 monoclonal antibody, a cleavable linker, and a cytotoxic payload (typically a topoisomerase I [TOP1] inhibitor). The antibody confers tumor specificity and mediates additional mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Cleavable linkers release payload in the acidic lysosomal environment of tumor cells, limiting systemic exposure. The drug-to-antibody ratio (DAR) balances payload delivery with immunogenicity and off-target toxicity. A key therapeutic advantage is the bystander effect: released payload diffuses into the tumor microenvironment and kills neighboring TROP2-low or TROP2-negative cells, potentially overcoming tumor heterogeneity 23. "On-target, off-tumor" toxicity in normal tissues expressing lower TROP2 levels—particularly skin and gastrointestinal epithelium—defines the therapeutic index ceiling for the class.
Approved TROP2 ADCs: Clinical Evidence by Indication
As of July 24, 2026, three TROP2 ADCs have received regulatory approval globally.
Table 1. Approved TROP2 ADCs: Key Clinical Data by Indication
| Agent | Company | Payload/Linker | Indication | Trial | Population | Median PFS (mo) | Median OS (mo) | ORR (%) | Key Safety Signals | Regulatory Status |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan (SG; Trodelvy) | Gilead Sciences | SN-38 / hydrolyzable cleavable | 1L mTNBC (monotherapy) | ASCENT-03, Phase III | 558 patients, untreated | 9.7 vs 6.9 (TPC); HR 0.62; p<0.0001 | Immature | 50 vs 47 (confirmed, per FDA approval data) | Neutropenia, diarrhea (boxed warning) | FDA approved June 2026 69 |
| Sacituzumab govitecan + pembrolizumab | Gilead / Merck | SN-38 / hydrolyzable cleavable | 1L mTNBC, PD-L1+ (CPS≥10) | ASCENT-04/KEYNOTE-D19, Phase III | 443 patients, untreated, CPS≥10 | 11.2 vs 7.8 (TPC+pembro); HR 0.65; p=0.0009 | Immature | 61 vs 55 | Neutropenia, diarrhea, immune-related AEs | FDA approved June 2026 69 |
| Sacituzumab govitecan | Gilead Sciences | SN-38 / hydrolyzable cleavable | HR+/HER2− metastatic BC, ≥2 prior lines | TROPiCS-02, Phase III | Heavily pretreated | 5.5 vs 4.0 (chemo) | 14.4 vs 11.2 | — | Neutropenia, diarrhea, leukopenia | FDA approved February 2023 10 |
| Datopotamab deruxtecan (Dato-DXd; Datroway) | Daiichi Sankyo / AstraZeneca | DXd (exatecan derivative) / tetrapeptide cleavable | 1L mTNBC, PD-L1 ineligible (monotherapy) | TROPION-Breast02, Phase III | 644 patients, untreated | 10.8 vs 5.6 (chemo); HR 0.57; p<0.0001 | 23.7 vs 18.7; HR 0.79; p=0.0290 | 64 vs 30 | Stomatitis, ILD/pneumonitis, ocular toxicity | FDA approved May 2026 118 |
| Datopotamab deruxtecan (Dato-DXd; Datroway) | Daiichi Sankyo / AstraZeneca | DXd / tetrapeptide cleavable | HR+/HER2− metastatic BC, post-endocrine/chemo | TROPION-Breast01, Phase III | Pretreated | 6.9 vs 4.9 (chemo) | Interim OS NS (as of primary analysis; final OS also NS, HR 1.01) | 36.4 vs 22.9 | Stomatitis, ILD/pneumonitis, ocular toxicity | FDA approved January 2025; >40 countries 58 |
| Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) | Kelun-Biotech / Merck | Belotecan derivative / 2-methylsulfonyl pyrimidine | Advanced TNBC, ≥2 prior lines | OptiTROP-Breast01, Phase III | Pretreated | 6.7 vs 2.5; HR 0.32; p<0.00001 | Not reached vs 9.4; HR 0.53; p=0.0005 | 45.4 vs 12.0 | Hematologic toxicity, stomatitis, dose interruptions | NMPA approved (China) 125 |
| Sacituzumab tirumotecan | Kelun-Biotech / Merck | Belotecan derivative / 2-methylsulfonyl pyrimidine | HR+/HER2− metastatic BC | OptiTROP-Breast02, Phase III | Post-endocrine/chemo | 8.3 vs 4.1; HR 0.35 | Favorable trend, immature | 41.5 vs 24.1 | Hematologic toxicity, stomatitis | NMPA approved February 2026 (China) 135 |
| Datopotamab deruxtecan (Dato-DXd) | Daiichi Sankyo / AstraZeneca | DXd / tetrapeptide cleavable | EGFR-mutated NSCLC, post-TKI+chemo | TROPION-Lung05 (pooled with Lung01) | n=137, ≥3 prior lines in 71.5% | 5.4 (overall); 5.8 (EGFR-mut) | 13.6 overall | 35.8; 43.6 (EGFR-mut) | Stomatitis 56.2%, nausea 54.7%, ILD 3.6% (1 grade 5) | FDA accelerated approval June 2025 16 |
Note: Cross-trial comparisons are indirect and limited by differences in patient population, line of therapy, comparator arms, and endpoint maturity. OS data for ASCENT-03 and ASCENT-04 were immature at regulatory submission. TPC = treatment of physician's choice; mTNBC = metastatic TNBC; NS = not statistically significant.
Key Clinical Interpretations
TROPION-Breast02 is notable as the first TROP2 ADC trial to demonstrate a statistically significant OS benefit in first-line mTNBC (HR 0.79; p=0.029), differentiating Dato-DXd from sacituzumab govitecan in that setting where OS data remain immature 11. However, direct head-to-head comparison between these agents has not been conducted, and the patient populations, comparator regimens, and geographic stratification differ across trials. Clinicians should weigh the OS signal from TROPION-Breast02 against Dato-DXd's more restrictive toxicity profile (see Safety section below) when making individualized treatment decisions. In the EVOKE-01 phase III trial evaluating sacituzumab govitecan versus docetaxel in previously treated metastatic NSCLC, the primary OS endpoint was not met, limiting sacituzumab govitecan's role in NSCLC outside investigational settings.
Safety, Tolerability, and Clinical Management
Table 2. Comparative Safety Profiles of Major TROP2 ADCs
| Adverse Event | Sacituzumab Govitecan | Dato-DXd | Sac-TMT |
|---|---|---|---|
| Neutropenia/leukopenia (Grade ≥3) | Common; boxed warning | Less frequent | Frequent; grade ≥3 in ~26% |
| Diarrhea | Prominent; boxed warning | Less common | Less prominent |
| Stomatitis/oral mucositis | Less common | Prominent; any grade ~63% | Prominent |
| Nausea/vomiting | Common | Common; ~55% any grade | Present |
| Ocular events | Less common | 38% any grade; grade ≥3 ~3% | Less documented |
| ILD/pneumonitis | Infrequent | 3–7% (tumor-type dependent); grade 5 reported | Less documented |
| Alopecia | Grade 1–2, common | Common | Present |
| Discontinuation due to AE | ~3.6–7% | ~5–10% | ~5% |
| Boxed warning | Diarrhea, neutropenia | ILD/pneumonitis, embryo-fetal toxicity | — |
Payload class is the dominant driver of adverse-event (AE) topology 25. Sacituzumab govitecan's SN-38 payload produces a profile dominated by neutropenia and diarrhea, requiring standard granulocyte colony-stimulating factor (G-CSF) support and loperamide prophylaxis. Patients harboring the UGT1A1*28 polymorphism (reduced SN-38 glucuronidation) require especially careful monitoring 9. Dato-DXd's DXd payload carries a different fingerprint: stomatitis (prophylactic antimicrobial mouthwash is standard), ocular toxicity requiring baseline and periodic ophthalmic assessment, and clinically significant though relatively infrequent ILD/pneumonitis, which mandates prompt investigation of any new respiratory symptoms and may require corticosteroids or treatment discontinuation 816. Sac-TMT's modified belotecan-derived linker was designed to enhance circulatory stability; early data suggest meaningful hematologic toxicity and stomatitis with frequent dose interruptions (51.5% vs 40.2% with chemotherapy) 12. Across all three agents, treatment discontinuation rates are generally 5–10%, and safety-related eligibility criteria—particularly excluding patients with prior ILD or significant corneal disease for Dato-DXd—should guide prescribing decisions 8.
Competitive Pipeline and Clinical-Trial Landscape
Table 3. TROP2 ADC Competitive Pipeline (as of 2026-07-24)
| Agent | Company | Payload/Linker | Indication(s) | Phase | Geography | Key Differentiation |
|---|---|---|---|---|---|---|
| ESG-401 (OQY-3258) | Levena Biopharma / Shanghai Escugen | TOP1 inhibitor | Breast cancer | Phase III | China | Late-stage China breast challenger 4 |
| FDA-018 | Shanghai Fudan-Zhangjiang | Monospecific TROP2 | Breast cancer | Phase III | China | China-focused registrational program 4 |
| DB-1305 (BNT-325) | BioNTech / Duality Biologics | TOP1 inhibitor | Breast cancer; NSCLC | Phase II | USA, China | Cross-indication mid-stage global asset 4 |
| MHB-036C | Shanghai Minghui | TOP1 inhibitor | NSCLC | Phase II | China | NSCLC-focused regional program 4 |
| DAC-002 (JS-108) | Hangzhou DAC Biotech / Junshi | Monospecific TROP2 | Breast cancer | Phase I | China | Early clinical entrant 4 |
| BL-M02D1 | Sichuan Biokin | Monospecific TROP2 | Breast cancer | Phase I | China | Early clinical entrant 4 |
| JSKN-016 | Suzhou Alphamab | TROP2/HER3 bispecific | Breast cancer; NSCLC | Preclinical | China | Bispecific differentiation 4 |
| YH-012 (RB-201) | Biocytogen / Radiance | TROP2/HER2 bispecific | Breast cancer; NSCLC | Preclinical | USA | Dual-target strategy 4 |
| VBC-103 | VelaVigo | TROP2/Nectin-4 bispecific | Breast cancer | Preclinical | China | Bispecific Nectin-4 strategy 4 |
| BCG-033 | Biocytogen | TROP2/PTK7 bispecific | Breast cancer | Preclinical | USA | Novel dual-target 4 |
The pipeline is heavily concentrated in breast cancer and stage IV NSCLC, with China serving as both the dominant development engine and a key commercialization market 4. A notable structural trend is the convergence of most programs around TOP1-associated payloads, which may shift future competitive differentiation away from target novelty toward tolerability optimization, dosing convenience, and biomarker-driven patient selection. The preclinical frontier is moving toward bispecific formats pairing TROP2 with HER3, HER2, EGFR, PTK7, or Nectin-4, aiming to address tumor heterogeneity and resistance 4.
In urothelial carcinoma (UC), Dato-DXd is being evaluated in the randomized Phase 2/3 TROPION-Urothelial03 trial, which compares Dato-DXd plus platinum chemotherapy versus gemcitabine plus platinum in patients progressing after enfortumab vedotin plus pembrolizumab. Enrollment began in September 2025 at approximately 276 sites globally; primary endpoints are ORR in Part A (dose-selection) and dual PFS/OS in Part B 1519. Mature efficacy data from this trial are not yet available in the retrieved materials. Earlier TROPION-PanTumor01 and PanTumor03 experience in UC showed qualitatively described durable efficacy and manageable safety, but exact numeric efficacy tables were not available in retrieved materials 1519. For sacituzumab govitecan in metastatic UC, a PubMed-indexed report noted activity across TROP2 expression levels, suggesting clinical utility even without high TROP2 enrichment, though exact numeric efficacy figures were not available in retrieved materials 20.
Sac-TMT received FDA breakthrough therapy designation in December 2024 for EGFR-mutated NSCLC (exon 19 deletion or L858R) progressing on or after TKI and platinum-based chemotherapy, with phase 1/2 data showing ORR of 43.6%, median duration of response (DoR) of 9.3 months, and 12-month OS rate of 70.6%. Multiple Phase III trials (TroFuse-004, TroFuse-009) are ongoing in NSCLC. Dato-DXd has also demonstrated early activity in gynecologic tumors: in a Phase II TROPION-PanTumor03 endometrial carcinoma cohort (n=40), ORR was 27.5% with median PFS 6.3 months; in an ovarian/fallopian/peritoneal cohort (n=35), ORR was 42.9% with median PFS 5.8 months 14.
Market Outlook and Strategic Implications
The rapid approval of two distinct TROP2 ADCs within 12 months (May–June 2026 for Dato-DXd and sacituzumab govitecan in first-line TNBC) signals the consolidation of TROP2-directed therapy as a standard-of-care pillar in breast cancer and an emerging anchor in EGFR-mutated NSCLC 611. Key strategic differentiators include:
Efficacy-safety balance: Dato-DXd's OS benefit in TROPION-Breast02 supports favorable reimbursement positioning in first-line PD-L1–ineligible mTNBC, but its more restrictive safety profile (ILD, ocular toxicity) may limit use in frail or high-risk patients. Sacituzumab govitecan's combination with pembrolizumab addresses PD-L1–positive mTNBC—a distinct and complementary population. These complementary regulatory niches reduce direct head-to-head competition in the near term.
Dosing convenience: Dato-DXd's every-3-week schedule may improve adherence compared with sacituzumab govitecan's biweekly (Days 1 and 8 of a 21-day cycle) dosing, a practical consideration in a real-world setting.
Adjacent ADC competition: HER2-directed ADCs (trastuzumab deruxtecan, trastuzumab emtansine) remain the standard for HER2-positive disease and do not directly compete; HER3-directed ADCs (patritumab deruxtecan) are in Phase II–III for EGFR-mutated NSCLC and may overlap with Dato-DXd and sac-TMT in that indication. Nectin-4– and B7-H3–directed ADCs address distinct patient populations with non-overlapping toxicity profiles, limiting direct displacement 14.
Resistance and sequencing: Heterogeneous TROP2 expression, upregulated drug efflux pumps, and altered intracellular trafficking represent emerging resistance mechanisms. Combination strategies with ICI, PARP inhibitors, and targeted therapies are under investigation to extend efficacy. Cross-ADC sequencing (e.g., TROP2 ADC after HER2 ADC or vice versa) is an area of active investigation with limited data.
Reimbursement and biomarkers: TROP2 immunohistochemistry (IHC) testing is feasible but TROP2 is broadly expressed across tumor types, limiting its current discriminatory role as a companion diagnostic. Payers are receptive to first-line TROP2 ADCs when OS or substantial PFS benefits are demonstrated. Real-world cost-effectiveness data and long-term follow-up will be critical in shaping formulary decisions through 2030 114.
China as a global engine: China has approved sac-TMT for TNBC and HR+/HER2− breast cancer, hosts the deepest ADC pipeline bench globally, and is the most active development geography for next-wave TROP2 ADC candidates 41213. Strategic alliances between Chinese biotech companies and multinational pharmaceutical companies (e.g., Kelun-Biotech/Merck, Duality Biologics/BioNTech) are accelerating global regulatory programs.
Clinical Implications: Summary for Practice
Clinicians evaluating first-line mTNBC can now choose between sacituzumab govitecan (monotherapy for patients not candidates for ICI; plus pembrolizumab for CPS≥10 PD-L1–positive) and Dato-DXd (for PD-L1–ineligible), with Dato-DXd's OS benefit differentiating it in the PD-L1–ineligible setting—though cross-trial comparisons must be interpreted cautiously given differing populations and comparators. In HR+/HER2− disease, sacituzumab govitecan retains OS-supported approval in later lines; sac-TMT's strong OptiTROP-Breast02 results suggest emerging competition in that segment. In EGFR-mutated NSCLC post-TKI and post-chemotherapy, Dato-DXd's accelerated FDA approval (June 2025) based on an ORR of 43.6% in the EGFR-mutant subpopulation (35.8% overall)16 and sac-TMT's breakthrough designation establish TROP2 ADCs as actionable options. Patient-specific factors—including PD-L1 status, prior therapy history, pulmonary and ocular comorbidities, and UGT1A1 genotype—should guide agent selection and monitoring strategies.